Acepodia gets FDA clearance to test a two-payload ADC in advanced liver cancer
The FDA has cleared Acepodia’s ACE723 IND, allowing the GPC3-targeted dual-payload antibody-drug conjugate to begin Phase 1 testing in unresectable or metastatic hepatocellular carcinoma.
